|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of neuroblastoma cells with the ODC1 inhibitor difluoromethylornithine (DFMO), although a promising therapeutic strategy, is only partially effective at impeding neuroblastoma cell growth due to activation of compensatory mechanisms resulting in increased polyamine uptake from the surrounding microenvironment.
|
30700572 |
2019 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By this study, a regulatory loop is proposed, wherein, ODC silencing in Y79 cells to result in decreased polyamine levels, thereby, leading to altered protein levels of Lin28b, MMP-2 and MMP-9, which falls in line with earlier studies in neuroblastoma.
|
29241071 |
2018 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Difluoromethylornithine (DFMO, an irreversible inhibitor of ornithine decarboxylase with minimal single-agent clinical response data) is being used for maintenance therapy of neuroblastoma.
|
30251395 |
2018 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The DHPS inhibitor GC7 (<i>N</i><sup>1</sup>-guanyl-1,7-diaminoheptane) and the ODC inhibitor α-difluoromethylornithine (DFMO) are target-specific and in combination induced synergistic effects in NB at concentrations that were not individually cytotoxic.
|
29295892 |
2018 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Difluoromethylornithine (DFMO, an irreversible inhibitor of ornithine decarboxylase) is reported to modulate polyamines to potentially attenuate proliferation of neuroblastoma cells.
|
29626790 |
2018 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To this end, the MYC-ODC axis presents an attractive target for managing cancers such as neuroblastoma, a pediatric malignancy in which <i>MYCN</i> gene amplification correlates with poor prognosis and high-risk disease.
|
30404920 |
2018 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes <i>ODC1</i> and <i>E2F2</i> DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation.
|
28209620 |
2017 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MYC coordinately regulates polyamine homeostasis as these essential cations support MYC functions, and drugs that antagonize polyamine sufficiency have synthetic-lethal interactions with MYC Neuroblastoma is a lethal tumor in which the MYC homologue MYCN, and ODC1, the rate-limiting enzyme in polyamine synthesis, are frequently deregulated so we tested optimized polyamine depletion regimens for activity against neuroblastoma.
|
27012811 |
2016 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Difluoromethylornithine (DFMO) is an inhibitor of ODC in clinical trials for children with NB.
|
25415050 |
2015 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We earlier presented evidence for a physical interaction between ODC and SPR and we showed that RNAi-mediated knockdown of SPR expression significantly reduced native ODC enzyme activity and impeded NB cell proliferation.
|
26093909 |
2015 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study investigated safety, response, pharmacokinetics, genetic and metabolic factors associated with ODC in a clinical trial of the ODC inhibitor difluoromethylornithine (DFMO) ± etoposide for patients with relapsed or refractory NB.
|
26018967 |
2015 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting ODC in NB cells produces many deleterious effects including G(1) cell cycle arrest, inhibition of cell proliferation, and decreased tumor growth, making ODC a promising target for drug interference.
|
23440295 |
2013 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ODC mRNA expression in NB tumors was significantly predictive of decreased overall survival probability and correlated with several unfavorable clinical NB characteristics (all p < 0.005).
|
19960435 |
2010 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
|
19147568 |
2009 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, elevated ODC1 (independent of MYCN amplification) was associated with reduced survival in a large independent neuroblastoma cohort.
|
19047152 |
2008 |
|
Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, we describe the development and validation of a functional MYCN reporter gene assay using neuroblastoma cells (NGP) which have been stably transfected with a luciferase gene construct under control of the ornithine decarboxylase gene promoter.
|
12880971 |
2003 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The R6ODC regulatory sequence was approximately equivalent to the CMV promoter in inducing expression of the neomycin resistance gene in c-MYC-expressing SW480 and HT-29 colon carcinoma cells and in N-MYC-expressing NB-1691 neuroblastoma cells.
|
11306486 |
2001 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
|
10933967 |
2000 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition in neuroblastomas, in which N-myc is amplified and overexpressed, only ODC was overexpressed in all cell lines, while all other target genes were expressed in only some of the cell lines.
|
9674700 |
1998 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells.
|
8761302 |
1996 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group.
|
8622876 |
1996 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We have previously shown that asparagine alone induces a 10-15-fold increase in ornithine decarboxylase (ODC) mRNA level in DF-40 mouse neuroblastoma cells.
|
7954361 |
1994 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report here that genomic DNA from 1 of 6 primary neuroblastoma tumors containing amplified N-myc also contains amplified sequences homologous to a hamster ODC cDNA.
|
2780050 |
1989 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A human neuroblastoma cell line with an altered ornithine decarboxylase.
|
6436232 |
1984 |